167 related articles for article (PubMed ID: 37004983)
1. Promise of dostarlimab in cancer therapy: Advancements and cross-talk considerations.
Babar Q; Saeed A; Murugappan S; Dhumal D; Tabish T; Thorat ND
Drug Discov Today; 2023 Jun; 28(6):103577. PubMed ID: 37004983
[TBL] [Abstract][Full Text] [Related]
2. Dostarlimab: From preclinical investigation to drug approval and future directions.
Cicala CM; Musacchio L; Scambia G; Lorusso D
Hum Vaccin Immunother; 2023 Dec; 19(1):2178220. PubMed ID: 36762991
[TBL] [Abstract][Full Text] [Related]
3. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models.
Kumar S; Ghosh S; Sharma G; Wang Z; Kehry MR; Marino MH; Neben TY; Lu S; Luo S; Roberts S; Ramaswamy S; Danaee H; Jenkins D
MAbs; 2021; 13(1):1954136. PubMed ID: 34313545
[TBL] [Abstract][Full Text] [Related]
4. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
5. Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer.
Alkholifi FK; Alsaffar RM
Medicina (Kaunas); 2022 Nov; 58(11):. PubMed ID: 36363529
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy.
Park UB; Jeong TJ; Gu N; Lee HT; Heo YS
Biochem Biophys Res Commun; 2022 Apr; 599():31-37. PubMed ID: 35168061
[TBL] [Abstract][Full Text] [Related]
7. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
Peng H; He X; Wang Q
Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.
Moreno V; Roda D; Pikiel J; Trigo J; Bosch-Barrera J; Drew Y; Kristeleit R; Hiret S; Bajor DL; Cruz P; Beck JT; Ghosh S; Dabrowski C; Antony G; Duan T; Veneris J; Zografos E; Subramanian J
Clin Lung Cancer; 2022 Nov; 23(7):e415-e427. PubMed ID: 35729005
[TBL] [Abstract][Full Text] [Related]
10. Dostarlimab for the treatment of endometrium cancer and other solid tumors.
Rubio-Pérez J; Hernández R; Hernández T; Doger B; Casado V; Moreno V
Drugs Today (Barc); 2021 Mar; 57(3):187-197. PubMed ID: 33729216
[TBL] [Abstract][Full Text] [Related]
11. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.
Oaknin A; Gilbert L; Tinker AV; Brown J; Mathews C; Press J; Sabatier R; O'Malley DM; Samouelian V; Boni V; Duska L; Ghamande S; Ghatage P; Kristeleit R; Leath C III; Guo W; Im E; Zildjian S; Han X; Duan T; Veneris J; Pothuri B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064011
[TBL] [Abstract][Full Text] [Related]
12. An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer.
Bartoletti M; Giorda G; Viel A; Fornasarig M; Zdjelar A; Segatto E; Sorio R; Corsetti S; Scalone S; Nicoloso MS; Pivetta T; Lucia E; Clemente N; Palazzari E; Canzonieri V; Puglisi F
Curr Oncol; 2022 Jul; 29(8):5209-5212. PubMed ID: 35892982
[TBL] [Abstract][Full Text] [Related]
13. Dostarlimab: First Approval.
Markham A
Drugs; 2021 Jul; 81(10):1213-1219. PubMed ID: 34106455
[TBL] [Abstract][Full Text] [Related]
14. A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.
Passiglia F; Bironzo P; Righi L; Listì A; Arizio F; Novello S; Volante M; Scagliotti GV
Clin Lung Cancer; 2021 Jan; 22(1):e63-e66. PubMed ID: 32917522
[TBL] [Abstract][Full Text] [Related]
15. Dostarlimab for recurrent mismatch repair-deficient endometrial cancer: A cost-effectiveness study.
Dioun S; Chen L; Melamed A; Gockley A; St Clair CM; Hou JY; Khoury-Collado F; Hur C; Elkin E; Accordino M; Hershman DL; Wright JD
BJOG; 2023 Jan; 130(2):214-221. PubMed ID: 36330672
[TBL] [Abstract][Full Text] [Related]
16. Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment.
Singh V; Sheikh A; Abourehab MAS; Kesharwani P
Biosensors (Basel); 2022 Aug; 12(8):. PubMed ID: 36005013
[TBL] [Abstract][Full Text] [Related]
17. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Paver EC; Cooper WA; Colebatch AJ; Ferguson PM; Hill SK; Lum T; Shin JS; O'Toole S; Anderson L; Scolyer RA; Gupta R
Pathology; 2021 Feb; 53(2):141-156. PubMed ID: 33388161
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
19. Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer.
Oaknin A; Tinker AV; Gilbert L; Samouëlian V; Mathews C; Brown J; Barretina-Ginesta MP; Moreno V; Gravina A; Abdeddaim C; Banerjee S; Guo W; Danaee H; Im E; Sabatier R
Future Oncol; 2021 Oct; 17(29):3781-3785. PubMed ID: 34427115
[TBL] [Abstract][Full Text] [Related]
20. Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer.
Yang Z; Wu G; Zhang X; Gao J; Meng C; Liu Y; Wei Q; Sun L; Wei P; Bai Z; Yao H; Zhang Z
Front Immunol; 2022; 13():1001444. PubMed ID: 36159842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
